法国2006-2019年结核病耐药定义修订与治疗结局
该研究回顾性分析了法国3个参考中心2006-2019年治疗的298例耐多药结核病(MDR TB)患者,其中205例(68.8%)为氟喹诺酮敏感MDR TB,93例(31.2%)为准广泛耐药/广泛耐药结核病(pre-XDR/XDR TB)。与氟喹诺酮敏感MDR TB相比,pre-XDR/XDR TB与更多空洞性肺病变和双侧病变相关,且需要更长治疗。总体202例(67.8%)获得良好治疗结局,pre-XDR/XDR TB(67.7%)与氟喹诺酮敏感MDR TB(67.8%)之间无显著差异(p=0.99)。pre-XDR/XDR TB与严重不良事件风险升高无关。
要点
- pre-XDR/XDR TB较氟喹诺酮敏感MDR TB更常伴空洞性肺病变和双侧病变,需更长治疗。
- 总体良好治疗结局67.8%,pre-XDR/XDR TB为67.7%,氟喹诺酮敏感MDR TB为67.8%,无显著差异(p=0.99)。
- pre-XDR/XDR TB与严重不良事件风险升高无关。
核心结论
- 在法国2006-2019年治疗的MDR TB患者中,pre-XDR/XDR TB与氟喹诺酮敏感MDR TB相比,良好治疗结局无显著差异(67.7% vs 67.8%;p=0.99)。
- pre-XDR/XDR TB与更多空洞性肺病变和双侧病变相关,且需要更长治疗,但未与严重不良事件风险升高相关。
研究设计与样本
- 回顾性研究,纳入法国3个参考中心2006-2019年治疗的298例MDR TB患者。
- 其中205例(68.8%)为氟喹诺酮敏感MDR TB,93例(31.2%)为pre-XDR/XDR TB。
主要发现
- 与氟喹诺酮敏感MDR TB相比,pre-XDR/XDR TB与更多空洞性肺病变和双侧病变相关,且需要更长治疗。
- 总体202例(67.8%)获得良好治疗结局,pre-XDR/XDR TB为67.7%,氟喹诺酮敏感MDR TB为67.8%,两组无显著差异(p=0.99)。
- pre-XDR/XDR TB与严重不良事件风险升高无关。
关键数值与推荐
- pre-XDR TB定义为MDR TB且对氟喹诺酮类额外耐药。
- XDR TB定义为对贝达喹啉或利奈唑胺额外耐药。
- pre-XDR/XDR TB常与治疗失败和毒性相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Definitions of resistance in multidrug-resistant tuberculosis (MDR TB) and extensively drug-resistant tuberculosis (XDR TB) have been updated. Pre-XDR TB, defined as MDR TB with additional resistance to fluoroquinolones, and XDR TB, with additional resistance to bedaquiline or linezolid, are frequently associated with treatment failure and toxicity. We retrospectively determined the effects of pre-XDR/XDR TB resistance on outcomes and safety of MDR TB treatment in France. The study included 298 patients treated for MDR TB at 3 reference centers during 2006-2019. Of those, 205 (68.8%) cases were fluoroquinolone-susceptible MDR TB and 93 (31.2%) were pre-XDR/XDR TB. Compared with fluoroquinolone-susceptible MDR TB, pre-XDR/XDR TB was associated with more cavitary lung lesions and bilateral disease and required longer treatment. Overall, 202 patients (67.8%) had favorable treatment outcomes, with no significant difference between pre-XDR/XDR TB (67.7%) and fluoroquinolone-susceptible MDR TB (67.8%; p = 0.99). Pre-XDR/XDR TB was not associated with higher risk for serious adverse events.
引用
- Kherabi Y, Fréchet-Jachym M, Rioux C, et al. Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006-2019. Emerg Infect Dis. 2022. PMID: 35997386. doi:10.3201/eid2809.220458
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。